Two phase II single-group, multicentre studies examining the use of vemurafenib, an oral BRAF inhibitor, were undertaken in patients with hairy cell leukaemia who had either relapsed after receiving a purine analogue or who were refractory to purine analogues. One study was undertaken in Italy, the other in the USA. The primary end point in the Italian study was the complete response rate (CRR) and in the USA study, it was the overall response rate (ORR). The CRR in the Italian study was 35% (nine of 26 patients) and 42% (10 of 24 patients) in the USA study. In the Italian study, the ORR was 96% (25 of 26 patients) in the Italian study; in the USA study it was 100% (24 of 24 patients).

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.